Abstract: Adagrasib (MRTX849) is a potent, orally available, and highly selective covalent inhibitor targeting the KRAS G12C mutation, a prevalent oncogenic driver in non-small cell lung cancer (NSCLC). For decades, the KRAS protein was considered "undruggable" due to its high affinity for intracellular GTP and the lack of deep binding pockets. However, the discovery of the switch-II cryptic pocket enabled the development of direct inhibitors. Adagrasib irreversibly binds to the mutant cysteine residue, locking the KRAS protein in its inactive GDP-bound state and halting downstream oncogenic signaling. Clinical trials, notably the KRYSTAL-1 study, have demonstrated significant and durable anti-tumor activity, including intracranial efficacy against brain metastases, leading to its FDA approval for pre-treated KRAS G12C-mutant NSCLC. Despite these breakthroughs, the long-term efficacy of adagrasib is limited by the inevitable emergence of acquired resistance, driven by secondary on-target mutations (e.g., Y96, H95) and off-target bypass signaling (e.g., MET, RET, and alternative RAS isoforms). Current research is heavily focused on overcoming these limitations through rational combination therapies—such as pairing adagrasib with SHP2, EGFR, or immune checkpoint inhibitors—and the development of next-generation active-state (ON) inhibitors and targeted protein degraders.
1. Introduction
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases [2][6]. Within NSCLC, the Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most frequently altered oncogene, present in up to 30% of cases, predominantly in patients with a positive smoking history and adenocarcinoma histology [1][4][6]. The most common KRAS alteration in NSCLC is the G12C mutation (a glycine-to-cysteine substitution at codon 12), which accounts for approximately 39% of all KRAS mutations in this disease [11].
Historically, KRAS was notoriously labeled as "undruggable." This reputation stemmed from the protein's exceptionally high affinity for cellular guanosine triphosphate (GTP) and a smooth topological surface lacking traditional deep binding pockets for small molecules [1][3][9]. Consequently, patients with KRAS-mutant NSCLC historically faced poor prognoses and relied on conventional platinum-based chemotherapy or immunotherapy [2][11]. The therapeutic landscape shifted dramatically with the discovery of a cryptic binding pocket in the switch-II region of the KRAS G12C mutant protein. This breakthrough paved the way for the development of direct, mutant-specific covalent inhibitors, notably sotorasib (AMG 510) and adagrasib (MRTX849) [1][7]. Adagrasib has since demonstrated robust clinical efficacy, earning FDA approval for the treatment of previously treated patients with KRAS G12C-mutant NSCLC [6][11].
2. Pharmacological Activity
Adagrasib exhibits potent pharmacological activity both in preclinical models and in the clinical setting. Preclinically, adagrasib demonstrated a broad spectrum of anti-tumor activity across various KRAS G12C-mutant cell lines and patient-derived xenograft models, resulting in significant tumor regression in up to 65-75% of NSCLC models [5][10]. Notably, preclinical data indicated that adagrasib possesses the ability to penetrate the blood-brain barrier and cerebrospinal fluid, suggesting potential efficacy against central nervous system (CNS) metastases [7].
Clinically, the efficacy of adagrasib was established primarily through the phase I/II KRYSTAL-1 trial (NCT03785249). In a cohort of 116 previously treated patients with KRAS G12C-mutant NSCLC receiving the recommended phase II dose of 600 mg twice daily, adagrasib yielded an objective response rate (ORR) of 42.9% to 45% and a disease control rate (DCR) of 79.5% to 96% [4][6][7]. The median progression-free survival (PFS) was reported at 6.5 to 6.9 months, with a median overall survival (OS) of 12.6 to 14.1 months [1][6][11]. Furthermore, in patients with stable, previously treated CNS metastases, adagrasib demonstrated a confirmed intracranial ORR of 33.3% and an intracranial PFS of 5.4 months, confirming its CNS penetrance and activity [1][6].
Regarding safety, adagrasib is generally tolerable, though treatment-related adverse events (TRAEs) are common. The most frequently reported TRAEs are gastrointestinal (diarrhea, nausea, vomiting), fatigue, and hepatic functional impairment (elevated AST/ALT levels) [4][6]. Grade 3 or 4 TRAEs occurred in approximately 30% to 45% of patients, occasionally necessitating dose reductions or treatment interruptions [1][6][7].
3. Molecular Mechanism of Action
Adagrasib functions as an oral, highly selective, covalent allosteric inhibitor of the KRAS G12C mutant protein [7][9]. The KRAS protein normally acts as a molecular switch, oscillating between an active GTP-bound state and an inactive GDP-bound state to regulate cellular proliferation and survival [5]. The G12C mutation impairs the intrinsic GTPase activity of KRAS, causing the protein to accumulate in the active, GTP-bound conformation, which continuously stimulates downstream oncogenic pathways [9].
Adagrasib specifically targets the mutant cysteine residue at position 12. It binds irreversibly to this residue within the switch-II pocket, effectively locking the KRAS G12C protein in its inactive, GDP-bound (OFF) state [7][12]. By trapping the protein in this inactive conformation, adagrasib prevents its affinity for GTP and subsequently halts the activation of critical downstream signaling cascades, most notably the RAF/MEK/ERK (MAPK) and PI3K/AKT/mTOR pathways [9][12]. This blockade ultimately impairs cell viability and induces tumor regression in KRAS G12C-driven cancers.
4. Structure-Activity Relationship (SAR)
The structural design of adagrasib was optimized to exploit the unique topography of the KRAS G12C switch-II cryptic pocket, which is formed by residues H95, Y96, and Q99 [13]. A critical feature of adagrasib's binding mechanism is the hydrogen-mediated bond formed between the hydroxyl group of the Y96 residue on the KRAS protein and the pyrimidine ring of the adagrasib molecule [13]. This specific interaction differentiates adagrasib from other inhibitors like sotorasib, which relies on water bridges with a carboxyl group to interact with Y96 [13].
The covalent bond formed with the mutant Cys12 residue is essential for the irreversible inhibition of the protein. Furthermore, the structural optimization of adagrasib confers favorable pharmacokinetic properties, notably a relatively long half-life of approximately 24.7 hours, compared to the 5.5-hour half-life of sotorasib [7][12]. This extended half-life supports continuous target inhibition and allows for its specific twice-daily dosing regimen (600 mg BID) [6][7].
5. Current Limitations
Despite the clinical success of adagrasib, its long-term efficacy is significantly hindered by the inevitable development of acquired drug resistance. Resistance mechanisms are highly heterogeneous and can be broadly categorized into on-target and off-target (bypass) alterations [4][6][13].
On-Target Resistance: Secondary mutations within the KRAS switch-II binding pocket can physically impede adagrasib from binding. Notable mutations include alterations at codons Y96 (e.g., Y96C/D), H95 (e.g., H95D/Q/R), and R68S [4][13][16]. Mutations at the Y96 codon are particularly problematic as they confer strong cross-resistance to both adagrasib and sotorasib [4]. Additionally, secondary activating mutations in KRAS (e.g., G12D, G12V, G12W) or KRAS amplification can reactivate the pathway [4][16].
Off-Target/Bypass Resistance: Tumor cells can bypass KRAS G12C inhibition by activating alternative signaling pathways. This includes the amplification or mutation of receptor tyrosine kinases (RTKs) such as MET and RET (e.g., CCDC6-RET fusions), as well as activating mutations in downstream or parallel effectors like NRAS, BRAF (e.g., V600E), MAP2K1, and PIK3CA [1][4][13]. Histological transformation from adenocarcinoma to squamous cell carcinoma or small cell lung cancer (SCLC) has also been observed as an escape mechanism [1][4].
Co-mutations and Toxicity: The genomic landscape of the tumor heavily influences adagrasib's efficacy. For instance, patients harboring concurrent KEAP1 mutations (particularly the STK11-wildtype/KEAP1-mutant profile) exhibit significantly inferior response rates [1][6]. Furthermore, the high incidence of gastrointestinal and hepatic toxicities remains a clinical challenge, frequently leading to dose reductions that may impact sustained target inhibition [6].
6. Future Perspectives
To overcome the limitations of monotherapy and combat acquired resistance, the future of KRAS G12C targeted therapy lies heavily in rational combination strategies and the development of next-generation agents.
Combination Therapies: Adagrasib is currently being evaluated in numerous clinical trials alongside other targeted agents. Combining adagrasib with SHP2 inhibitors (e.g., TNO155) or SOS1 inhibitors aims to block upstream RTK-mediated feedback reactivation of wild-type RAS isoforms [1][2][5]. Combinations with EGFR inhibitors (such as cetuximab or afatinib) have shown promise, particularly in colorectal cancer, and are being explored in NSCLC to prevent bypass signaling [7][11]. Additionally, trials are investigating the synergy between adagrasib and immune checkpoint inhibitors (e.g., pembrolizumab) to leverage the immunomodulatory effects of KRAS inhibition [5][11].
Next-Generation Inhibitors and Degraders: To address resistance mediated by the active GTP-bound state of KRAS, novel tri-complex KRAS G12C (ON) inhibitors (such as RMC-6291) are in preclinical and early clinical development. These agents bind to the active conformation and have shown superiority over OFF-state inhibitors in overcoming RTK-mediated escape mechanisms [7]. Furthermore, Proteolysis Targeting Chimeras (PROTACs) are being developed to induce the targeted degradation of the mutant KRAS protein entirely, offering a potential solution to both on-target mutations and scaffolding-related resistance [4].
Finally, ongoing phase III trials, such as KRYSTAL-12 (comparing adagrasib to docetaxel in pre-treated NSCLC), will provide definitive data to solidify adagrasib's position in the standard of care and guide its optimal sequencing in the therapeutic algorithm [1][4][6].
